Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405
- Citation:
- J Clin Oncol vol 33 (suppl) abstr 3585
- Meeting Instance:
- ASCO 2015
- Year:
- 2015
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- This research was also supported by Bristol-Myers Squibb, Genentech, and Pfizer
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, CA31946
- Corr. Author:
- Authors:
- Volker Heinemann Donna Niedzwiecki Rachel Pearline Heinz-Josef Lenz Federico Innocenti Howard S. Hochster Axel Grothey Richard M. Goldberg Robert J. Mayer Richard L. Schilsky Monica M. Bertagnolli Charles D. Blanke Alan P. Venook Sebastian Stinzing Bert H. O'Neil
- Networks:
- CA011, CA136, LAPS-IN007, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-OH007, OR013
- Study
- CALGB-80405
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: